Status:

COMPLETED

Efficacy & Safety of Seroquel Plus Mood Stabilizer in the Maintenance of Bipolar I Disorder

Lead Sponsor:

AstraZeneca

Conditions:

Bipolar I Disorder

Eligibility:

All Genders

18+ years

Phase:

PHASE3

Brief Summary

The purpose of this study is to determine whether quetiapine when used as adjunct to lithium or divalproex is safe and effective in the maintenance treatment of adult patients with Bipolar I Disorder....

Eligibility Criteria

Inclusion

  • A diagnosis of Bipolar I Disorder, Most recent episode Manic (296.4x), or Bipolar I Disorder, Most Recent Episode Depressed (296.5x), or Bipolar I Disorder, Most recent Episode Mixed (296.6x), with or without psychotic features, as defined by Diagnostic and Statistical Manual of Mental Disorders - Fourth Edition (DSM-IV)
  • At least 1 manic, depressed, or mixed episode in the 2 years prior to the index episode.
  • Able to understand and comply with the requirements of the study.

Exclusion

  • Diagnosis of an anxiety disorder as defined by DSM-IV, which was treated with medication within the past year.
  • Known intolerance or lack of response to quetiapine fumarate or to the assigned mood stabilizer, as judged by the investigator.
  • Previously randomized into this study or D1447C00126

Key Trial Info

Start Date :

April 1 2004

Trial Type :

INTERVENTIONAL

End Date :

October 1 2006

Estimated Enrollment :

710 Patients enrolled

Trial Details

Trial ID

NCT00107731

Start Date

April 1 2004

End Date

October 1 2006

Last Update

March 25 2009

Active Locations (166)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 42 (166 locations)

1

Research Site

Birmingham, Alabama, United States

2

Research Site

Beverly Hills, California, United States

3

Research Site

Chula Vista, California, United States

4

Research Site

Redlands, California, United States